Company profile
SUPERNUS PHARMACEUTICALS, INC.
NASDAQ:SUPNBiotechnology: Pharmaceutical Preparations
Drug pipeline (10)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| QELBREE | approved | $89.2MQ2 2026 | 6 | approved |
| GOCOVRI | approved | $37.5MQ2 2026 | 0 | — |
| ONAPGO | approved | $13.5MQ2 2026 | 2 | approved |
| OXTELLAR XR | approved | $8.8MQ2 2026 | 8 | approved |
| TROKENDI XR | approved | $8.4MQ2 2026 | 61 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (61)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05358821 | phase2 | completed | 2022-05-26 | 2024-02-29 | Supernus Pharmaceuticals, Inc. | 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease |
| NCT01114854 | phase1 | completed | 2010-06-01 | 2010-12-01 | Supernus Pharmaceuticals, Inc. | A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM) |
| NCT05059600 | phase4 | completed | 2021-10-08 | 2022-07-14 | Supernus Pharmaceuticals, Inc. | A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting |
| NCT02477618 | phase3 | completed | 2015-06-01 | 2017-07-18 | Supernus Pharmaceuticals, Inc. | A Study With SAGE-547 for Super-Refractory Status Epilepticus |
| NCT03844906 | phase1 | completed | 2018-12-27 | 2019-03-18 | Supernus Pharmaceuticals, Inc. | A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects |
FDA applications (9)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 214056 | 2025-02-03 | NDA | MDD US OPERATIONS LLC A SUB OF SUPERNUS PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 211964 | 2021-04-02 | NDA | SUPERNUS PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 211371 | 2019-06-17 | NDA | SAGE THERAPEUTICS LLC A WHOLLY OWNED SUB OF SUPERNUS PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 209410 | 2018-02-16 | NDA | SUPERNUS PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 208944 | 2017-08-24 | NDA | SUPERNUS PHARMACEUTICALS INC | |||||
Loading… | ||||||||